Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock Holdings Lifted by DCF Advisers LLC

DCF Advisers LLC increased its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 2.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 290,684 shares of the company’s stock after acquiring an additional 6,000 shares during the quarter. DCF Advisers LLC owned 0.96% of Lifecore Biomedical worth $1,491,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in LFCR. Allegheny Financial Group LTD purchased a new position in Lifecore Biomedical during the 2nd quarter valued at about $52,000. Renaissance Technologies LLC purchased a new position in Lifecore Biomedical during the second quarter valued at approximately $56,000. SG Americas Securities LLC acquired a new position in Lifecore Biomedical in the 1st quarter valued at approximately $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Lifecore Biomedical in the 1st quarter valued at approximately $58,000. Finally, Boston Partners purchased a new stake in Lifecore Biomedical in the 1st quarter worth approximately $104,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Trading Up 8.1 %

NASDAQ:LFCR opened at $5.62 on Friday. The company has a market capitalization of $170.41 million, a P/E ratio of -1.68 and a beta of 0.95. The stock’s 50 day moving average price is $5.29 and its 200 day moving average price is $5.74. The company has a debt-to-equity ratio of 12.90, a quick ratio of 1.06 and a current ratio of 2.08. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Monday, August 26th. The company reported ($0.15) EPS for the quarter. The business had revenue of $37.89 million during the quarter. Lifecore Biomedical had a negative return on equity of 515.12% and a net margin of 9.37%. On average, research analysts forecast that Lifecore Biomedical, Inc. will post -0.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on LFCR shares. Barrington Research cut shares of Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 28th. Craig Hallum assumed coverage on Lifecore Biomedical in a research note on Thursday, September 5th. They issued a “buy” rating and a $8.00 target price on the stock.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.